Advertisement
Short Communication| Volume 118, P116-118, May 2022

Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine

Open AccessPublished:February 19, 2022DOI:https://doi.org/10.1016/j.ijid.2022.02.036
Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine
Previous ArticleDelirium severity in critical patients with COVID-19 from an Infectious Disease Intensive Care Unit
Next ArticleEffectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan

      Highlights

      • •
        Health care workers (HCWs) are being prioritized to receive COVID-19 vaccine booster dose.
      • •
        Ninety fully vaccinated HCWs with the CoronaVac vaccine received the third booster dose of the Moderna vaccine.
      • •
        After the third dose, the antibody to S protein was between 20 837 and 41 646 U/mL.
      • •
        Age was negatively associated with antibodies level after the third booster vaccination.

      Abstract

      Background

      Health care workers (HCWs), a high-risk group for contracting COVID-19 disease, are being prioritized to receive COVID-19 vaccination. A third dose messenger RNA (mRNA) vaccine, mRNA-1273 (Moderna), after 2 doses of inactivated vaccine (CoronaVac), has been used to increase the level of protection against SARS-CoV-2 among Indonesian HCWs. However, data regarding antibody response after mRNA-1273 booster dose are limited.

      Objective

      To evaluate the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein (anti-S) titers induced by the third mRNA-1273 vaccine among fully vaccinated HCWs with CoronaVac.

      Results

      A total of 90 HCWs with no history of SARS-CoV-2 infection and who had received the third dose of vaccination were included in this study. The mRNA-1273 vaccine booster was administered 6 months after completing primary vaccination with CoronaVac. After the third dose, the anti-S antibodies level significantly increased, from a median of 41.7 U/mL (interquartile range [IQR], 22.4-92.5) to 28 394 U/mL (IQR, 20 837-41 646) (p <0.0001). After the third dose, seropositivity with the anti-S antibodies level >210 U/mL was observed in all HCWs. Age was negatively associated with the anti-S antibodies level after the mRNA-1273 booster.

      Conclusion

      The heterologous prime booster with CoronaVac and mRNA-1273 vaccine booster elicit a pronounced antibody response against SARS-CoV-2 infection.

      Keywords

      Health care workers (HCWs) are at the frontline battling against the COVID-19 pandemic and are categorized as a priority target group for COVID-19 vaccines. CoronaVac (Sinovac Life Sciences, China), an inactivated SARS-CoV-2 vaccine, was the initially available vaccine platform and primarily administered to Indonesian HCWs. Although previous clinical trial studies in China (
      • Zhang Y.
      • Zeng G.
      • Pan H.
      • Li C.
      • Hu Y.
      • Chu K.
      • et al.
      Safety, tolerability, and immunogenicity of an inactivated sars-cov-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
      Lancet Infect Dis. 2021; 21: 181-192https://doi.org/10.1016/S1473-3099(20)30843-4
      ) and Turkey (
      • Tanriover M.D.
      • Doganay H.L.
      • Akova M.
      • Guner H.R.
      • Azap A.
      • Akhan S.
      • et al.
      Efficacy and safety of an inactivated whole-virion sars-cov-2 vaccine (coronavac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in turkey.
      Lancet. 2021; 398: 213-222https://doi.org/10.1016/S0140-6736(21)01429-X
      ) have evidenced the immunogenicity of 2-dose CoronaVac, the antibody levels predictive for SARS-CoV-2 protection has declined over time (
      • Mok C.K.P.
      • Cohen C.A.
      • Cheng S.M.S.
      • Chen C.
      • Kwok K.O.
      • Yiu K.
      • et al.
      Comparison of the immunogenicity of bnt162b2 and coronavac covid-19 vaccines in hong kong.
      Respirology. 2021; https://doi.org/10.1111/resp.14191
      ). To address the potential waning immunity, the administration of the third COVID-19 vaccine dose for Indonesian HCWs has started in August 2021. The SARS-CoV-2 messenger RNA (mRNA) (mRNA-1273, Moderna) vaccine has been used as the third (booster) dose for Indonesian HCWs. This study aims to assess the total antibodies specific to the receptor-binding domain (RBD) of the SARS-CoV-2 S protein (anti-S) titers elicited after the third mRNA-1273 dose among fully vaccinated HCWs with CoronaVac.
      A total of 90 HCWs at Siloam Teaching Hospital, Indonesia, were included in this retrospective cohort study. The inclusion criteria were: (1) fully vaccinated HCWs with CoronaVac who received the mRNA-1273 vaccine as the third dose between August 10, 2021, and September 24, 2021, (2) HCWs who had not previously been infected with SARS-CoV-2, as confirmed by negative reverse-transcriptase PCR testing that was performed regularly in the hospital.
      Serological testing for total antibodies specific to the RBD of the SARS-CoV-2 S protein (anti-S) was performed using the Elecsys anti-SARS-CoV-2 S electrochemiluminescence immunoassay (ECLIA) with the Cobas e601 analyzer (Roche Diagnostics), according to the manufacturer's instruction. A test result ≥ 0.8 U/mL or more was considered positive. Samples above 250 U/mL were diluted further (1:10, 1:100, and 1:1000) within the measurement range of the assay (0.4-250 U/mL).
      The median age of participants was 31 years (interquartile [IQR], 26-44), and 88% were female (Table 1). The third vaccine was administered a median (IQR) of 178 (176-191) days after the second vaccination. The anti-S antibodies level increased significantly after the third vaccination from a median of 41.7 U/mL (IQR, 22.4-92.5) to 28 394 U/mL (IQR, 20 837-41 646) (p <0.0001). All HCWs had positive anti-S antibodies, ≥ 0.8 U/mL, before and after the third vaccination. However, the percentage of HCWs with anti-S antibodies level > 210 U/mL was significantly different before and after the third vaccination (11% vs 100%, p <0.0001). A significant negative correlation was observed between the anti-S antibodies level and the age of the participant after the third dose (r = -0.219; p = 0.03), but not before the third dose of vaccination (r = -0.053; p = 0.61). Age remained independently associated with the log2-transformed anti-S antibodies level after mRNA-1273 booster dose in multiple linear regression analysis (p = 0.003, Table 2).
      Table 1Baseline demographic and characteristics before and after the third mRNA-1273 dose
      CharacteristicsAll (n=90)
      Age (years), median (IQR)31 (26-44)
      Gender, n (%)
       Female79 (88)
       Male11 (12)
      Analysis before third dose
       Days after second vaccine, median (IQR)144 (142-146)
       Total antibodies titers, median (IQR), U/mL41.7 (22.4-92.5)
       The positivity anti-S antibodies, n (%)
       ≥ 0.8 U/mL90 (100%)
       > 210 U/mL10 (11%)
      Analysis after third dose
       Days after second vaccine, median (IQR)236 (234-237)
       Days after third vaccine, median (IQR)57 (44-60)
       Total antibodies titers, median (IQR), U/mL28 394 (20 837-41 646)
       The positivity anti-S antibodies, n (%)
       ≥ 0.8 U/mL90 (100%)
       > 210 U/mL90 (100%)
      Interval between second and third dose (days), median (IQR)178 (176-191)
      IQR = interquartile range
      Table 2Multiple linear regression on log2 transformation of anti-S antibodies level
      Variablesβ (95% CI)p-value
      Age (years)-0.024 (-0.040 to -0.008)0.003
      Gender
       FemaleReference
       Male-0.205 (-0.677 to 0.267)0.391
      Interval between the third dose vaccination and testing (days)-0.039 (-0.053 to -0.026)<0.0001
      The antibody level, in particular antibody toward RBD of the S protein (anti-S), has been shown to correlate with virus-neutralizing titers, suggesting the quantification of this antibody can be predictive for SARS-CoV-2 protection (
      • Salazar E.
      • Kuchipudi S.V.
      • Christensen P.A.
      • Eagar T.
      • Yi X.
      • Zhao P.
      • et al.
      Convalescent plasma anti-sars-cov-2 spike protein ectodomain and receptor-binding domain igg correlate with virus neutralization.
      J Clin Invest. 2020; 130: 6728-6738https://doi.org/10.1172/JCI141206
      ). Similar to other studies (
      • Kwok S.L.
      • Cheng S.M.
      • Leung J.N.
      • Leung K.
      • Lee C.-K.
      • Peiris J.M.
      • et al.
      Waning antibody levels after vaccination with mrna bnt162b2 and inactivated coronavac covid-19 vaccines in hong kong blood donors.
      medRxiv. 2021; (2021.2012.2005.21267330)https://doi.org/10.1101/2021.12.05.21267330
      ;
      • Mok C.K.P.
      • Cohen C.A.
      • Cheng S.M.S.
      • Chen C.
      • Kwok K.O.
      • Yiu K.
      • et al.
      Comparison of the immunogenicity of bnt162b2 and coronavac covid-19 vaccines in hong kong.
      Respirology. 2021; https://doi.org/10.1111/resp.14191
      ), our study has shown that the decline of anti-S antibodies occurred quickly among the fully vaccinated HCWs with CoronaVac (
      • Cucunawangsih C.
      • Wijaya R.S.
      • Lugito N.P.H.
      • Suriapranata I.
      Antibody response to the inactivated sars-cov-2 vaccine among healthcare workers, indonesia.
      Int J Infect Dis. 2021; 113: 15-17https://doi.org/10.1016/j.ijid.2021.09.078
      ). Therefore, considering the short-term immune response after CoronaVac vaccination and the occupational risk of HCWs for acquiring SARS-CoV-2 infection, HCWs are prioritized to receive a booster dose of the mRNA-1273 vaccine.
      The heterologous boosting strategy refers to administering a vaccine that differs from the previous vaccine platform, potentially improving the immunogenicity and expanding the breadth of cellular and humoral immunity against current SARS-CoV-2 variants of concern (
      • Barros-Martins J.
      • Hammerschmidt S.I.
      • Cossmann A.
      • Odak I.
      • Stankov M.V.
      • Morillas Ramos G.
      • et al.
      Immune responses against sars-cov-2 variants after heterologous and homologous chadox1 ncov-19/bnt162b2 vaccination.
      Nat Med. 2021; 27: 1525-1529https://doi.org/10.1038/s41591-021-01449-9
      ;
      • Munro A.P.S.
      • Janani L.
      • Cornelius V.
      • Aley P.K.
      • Babbage G.
      • Baxter D.
      • et al.
      Safety and immunogenicity of seven covid-19 vaccines as a third dose (booster) following two doses of chadox1 ncov-19 or bnt162b2 in the uk (cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial.
      Lancet. 2021; 398: 2258-2276https://doi.org/10.1016/S0140-6736(21)02717-3
      ). Heterologous boosting of CoronaVac with mRNA vaccine have shown to induce a greater antibody response compared with other booster vaccine platforms and also produce neutralizing antibodies against ancestral, Delta, and Omicron SARS-CoV-2 variants (
      • Cheng S.M.S.
      • Mok C.K.P.
      • Leung Y.W.Y.
      • Ng S.S.
      • Chan K.C.K.
      • Ko F.W.
      • et al.
      Neutralizing antibodies against the sars-cov-2 omicron variant following homologous and heterologous coronavac or bnt162b2 vaccination.
      Nat Med. 2022; https://doi.org/10.1038/s41591-022-01704-7
      ;
      • Costa Clemens S.A.
      • Weckx L.
      • Clemens R.
      • Almeida Mendes A.V.
      • Ramos Souza A.
      • Silveira M.B.V.
      • et al.
      Heterologous versus homologous covid-19 booster vaccination in previous recipients of two doses of coronavac covid-19 vaccine in brazil (rhh-001): A phase 4, non-inferiority, single blind, randomised study.
      Lancet. 2022; 399: 521-529https://doi.org/10.1016/S0140-6736(22)00094-0
      ;
      • Perez-Then E.
      • Lucas C.
      • Monteiro V.S.
      • Miric M.
      • Brache V.
      • Cochon L.
      • et al.
      Neutralizing antibodies against the sars-cov-2 delta and omicron variants following heterologous coronavac plus bnt162b2 booster vaccination.
      Nat Med. 2022; https://doi.org/10.1038/s41591-022-01705-6
      ). The mRNA-1273 vaccine booster was administered 6 months after the second CoronaVac vaccination. Administering the vaccine booster led to a strong immune boost in all HCWs, with the anti-S antibodies significantly increasing to > 210 U/mL. This level is suggested by the United States Food and Drug Administration for the high titer of anti-SARS-CoV-2 antibodies in convalescent plasma for COVID-19 treatment as measured using the Elecsys anti-SARS-CoV-2 assay. Furthermore, agreeing with previous studies (
      • Abu Jabal K.
      • Ben-Amram H.
      • Beiruti K.
      • Batheesh Y.
      • Sussan C.
      • Zarka S.
      • et al.
      Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the bnt162b2 mrna covid-19 vaccine: Real-world evidence from healthcare workers, israel, december 2020 to january 2021.
      Euro Surveill. 2021; 26https://doi.org/10.2807/1560-7917.ES.2021.26.6.2100096
      ;
      • Steensels D.
      • Pierlet N.
      • Penders J.
      • Mesotten D.
      • Heylen L.
      Comparison of sars-cov-2 antibody response following vaccination with bnt162b2 and mrna-1273.
      JAMA. 2021; 326: 1533-1535https://doi.org/10.1001/jama.2021.15125
      ), our result showed that age was negatively associated with the antibody response after the third dose of vaccine. The reduced vaccine response in older adults is possibly related to immune senescence (
      • Poland G.A.
      • Ovsyannikova I.G.
      • Kennedy R.B.
      Personalized vaccinology: A review.
      Vaccine. 2018; 36: 5350-5357https://doi.org/10.1016/j.vaccine.2017.07.062
      ).
      Limitations of this study include a single-center study, a small sample size, lack of data on cellular immunity and neutralizing antibodies, and the short follow-up. In conclusion, our study showed that a heterologous regimen of 2 doses of prime CoronaVac followed by a single mRNA-1273 booster dose significantly enhances anti-S antibodies levels, which could improve protection against SARS-CoV-2 infection. In the current condition where Indonesia has started the COVID-19 booster vaccination program for the general population, our finding provides valuable information regarding the serologic response that can be achieved with heterologous prime booster vaccination using a CoronaVac and mRNA-1273 vaccine booster.

      Declaration of Competing Interest

      The authors have declared no conflicts of interest.

      Funding

      No external funding was received.

      Ethics Approval

      This study was approved by the research ethics committee of the Faculty Medicine of Pelita Harapan University (No: 137/K-LKJ/ETIK/IV/2021).

      Author Contributions

      Designing research studies (CC, RW, NL), acquiring data (CC), analyzing data (CC, RW, NL, IS), interpreting the results (CC, RW, NL, IS), and writing the manuscript (CC, RW, NL, IS).

      References

        • Abu Jabal K.
        • Ben-Amram H.
        • Beiruti K.
        • Batheesh Y.
        • Sussan C.
        • Zarka S.
        • et al.
        Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the bnt162b2 mrna covid-19 vaccine: Real-world evidence from healthcare workers, israel, december 2020 to january 2021.
        Euro Surveill. 2021; 26https://doi.org/10.2807/1560-7917.ES.2021.26.6.2100096
        View in Article
        • Barros-Martins J.
        • Hammerschmidt S.I.
        • Cossmann A.
        • Odak I.
        • Stankov M.V.
        • Morillas Ramos G.
        • et al.
        Immune responses against sars-cov-2 variants after heterologous and homologous chadox1 ncov-19/bnt162b2 vaccination.
        Nat Med. 2021; 27: 1525-1529https://doi.org/10.1038/s41591-021-01449-9
        View in Article
        • Cheng S.M.S.
        • Mok C.K.P.
        • Leung Y.W.Y.
        • Ng S.S.
        • Chan K.C.K.
        • Ko F.W.
        • et al.
        Neutralizing antibodies against the sars-cov-2 omicron variant following homologous and heterologous coronavac or bnt162b2 vaccination.
        Nat Med. 2022; https://doi.org/10.1038/s41591-022-01704-7
        View in Article
        • Costa Clemens S.A.
        • Weckx L.
        • Clemens R.
        • Almeida Mendes A.V.
        • Ramos Souza A.
        • Silveira M.B.V.
        • et al.
        Heterologous versus homologous covid-19 booster vaccination in previous recipients of two doses of coronavac covid-19 vaccine in brazil (rhh-001): A phase 4, non-inferiority, single blind, randomised study.
        Lancet. 2022; 399: 521-529https://doi.org/10.1016/S0140-6736(22)00094-0
        View in Article
        • Cucunawangsih C.
        • Wijaya R.S.
        • Lugito N.P.H.
        • Suriapranata I.
        Antibody response to the inactivated sars-cov-2 vaccine among healthcare workers, indonesia.
        Int J Infect Dis. 2021; 113: 15-17https://doi.org/10.1016/j.ijid.2021.09.078
        View in Article
        • Kwok S.L.
        • Cheng S.M.
        • Leung J.N.
        • Leung K.
        • Lee C.-K.
        • Peiris J.M.
        • et al.
        Waning antibody levels after vaccination with mrna bnt162b2 and inactivated coronavac covid-19 vaccines in hong kong blood donors.
        medRxiv. 2021; (2021.2012.2005.21267330)https://doi.org/10.1101/2021.12.05.21267330
        View in Article
        • Mok C.K.P.
        • Cohen C.A.
        • Cheng S.M.S.
        • Chen C.
        • Kwok K.O.
        • Yiu K.
        • et al.
        Comparison of the immunogenicity of bnt162b2 and coronavac covid-19 vaccines in hong kong.
        Respirology. 2021; https://doi.org/10.1111/resp.14191
        View in Article
        • Munro A.P.S.
        • Janani L.
        • Cornelius V.
        • Aley P.K.
        • Babbage G.
        • Baxter D.
        • et al.
        Safety and immunogenicity of seven covid-19 vaccines as a third dose (booster) following two doses of chadox1 ncov-19 or bnt162b2 in the uk (cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial.
        Lancet. 2021; 398: 2258-2276https://doi.org/10.1016/S0140-6736(21)02717-3
        View in Article
        • Perez-Then E.
        • Lucas C.
        • Monteiro V.S.
        • Miric M.
        • Brache V.
        • Cochon L.
        • et al.
        Neutralizing antibodies against the sars-cov-2 delta and omicron variants following heterologous coronavac plus bnt162b2 booster vaccination.
        Nat Med. 2022; https://doi.org/10.1038/s41591-022-01705-6
        View in Article
        • Poland G.A.
        • Ovsyannikova I.G.
        • Kennedy R.B.
        Personalized vaccinology: A review.
        Vaccine. 2018; 36: 5350-5357https://doi.org/10.1016/j.vaccine.2017.07.062
        View in Article
        • Salazar E.
        • Kuchipudi S.V.
        • Christensen P.A.
        • Eagar T.
        • Yi X.
        • Zhao P.
        • et al.
        Convalescent plasma anti-sars-cov-2 spike protein ectodomain and receptor-binding domain igg correlate with virus neutralization.
        J Clin Invest. 2020; 130: 6728-6738https://doi.org/10.1172/JCI141206
        View in Article
        • Steensels D.
        • Pierlet N.
        • Penders J.
        • Mesotten D.
        • Heylen L.
        Comparison of sars-cov-2 antibody response following vaccination with bnt162b2 and mrna-1273.
        JAMA. 2021; 326: 1533-1535https://doi.org/10.1001/jama.2021.15125
        View in Article
        • Tanriover M.D.
        • Doganay H.L.
        • Akova M.
        • Guner H.R.
        • Azap A.
        • Akhan S.
        • et al.
        Efficacy and safety of an inactivated whole-virion sars-cov-2 vaccine (coronavac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in turkey.
        Lancet. 2021; 398: 213-222https://doi.org/10.1016/S0140-6736(21)01429-X
        View in Article
        • Zhang Y.
        • Zeng G.
        • Pan H.
        • Li C.
        • Hu Y.
        • Chu K.
        • et al.
        Safety, tolerability, and immunogenicity of an inactivated sars-cov-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
        Lancet Infect Dis. 2021; 21: 181-192https://doi.org/10.1016/S1473-3099(20)30843-4
        View in Article

      Article info

      Publication history

      Published online: February 19, 2022
      Accepted: February 16, 2022
      Received in revised form: February 16, 2022
      Received: February 1, 2022

      Identification

      DOI: https://doi.org/10.1016/j.ijid.2022.02.036

      Copyright

      © 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX